INTRODUCTION

When people use medication, any number of outcomes is possible. Most commonly, the patient benefits from the pharmacotherapeutic interventions; however, there is only a fine line of distinction between the anticipated outcome and side effect of the drug. Any deviation from the intended beneficial effect of medication can result in drug-related problem (DRP) [1]. Nowadays, the problems related to drugs represent a major cause of morbidity and are thought to cause between 10% and 30% of all hospital admissions in elderly patients [2].

DRPs pose a challenge to the physician, pharmacist, and other health-care professionals since it alters the expected therapeutic outcome. Furthermore, it increases the health-care costs of the patient. Estimates have shown that for every US $ 1 spent on drugs, US $ 1.33 is consumed to treat DRPs [3]. Since the economic impact of DRPs is high, it is important to identify and resolve them. To do that, it is important to categorize the DRPs. There are 8 major types of DRPs that have been identified.

Adverse drug reaction which is the most common DRP is defined as “any response that is noxious and unintended and that occurs at doses normally used in humans for prophylaxis, diagnosis, or treatment, excluding a failure to accomplish the intended purpose. A drug interaction is “a medical problem resulting from a drug–drug, drug–food, or drug–laboratory interaction”; drug non-compliance “the extent to which the patient’s drug-taking behavior” (in terms of taking medication) coincides with the prescription” [4]; failure to receive drugs is a “medical problem that resulted from not receiving a drug” (e.g., for pharmaceutical, psychological, sociological, or economic reasons); improper drug selection was the taking of a wrong drug (other than one prescribed by the physician); drug overdose was a medical problem treated with too much of the correct drug (toxicity); and untreated indication was a medical problem that required drug therapy (an indication for drug use), but for which the patient was not receiving a drug.

Corrective, preventive, and educational strategies should concentrate on the most frequently reported populations, diseases, and medications. The study addresses the proper use of medications to ensure the best outcomes of pharmacological interventions.

METHODS

This prospective cohort observational study was conducted at the EMD in PSG Hospital, Coimbatore. The study was carried out over a period of 6 months from February to July 2019 and was approved by the Institutional Ethics Committee at PSG.

A sample of 1000 patients was selected and observed. A patient is included if admitted through EMD due to DRPs during the study period. The data were collected to determine the incidence of admissions through the EMD due to DRPs, identify them, and to classify them based on strand et al. classification mentioned earlier. The study also involved the understanding of major organ system involved in the DRP, major causative drug, and the major risk factor for DRPs. The statistical significance was calculated using odds ratio (*p<0.05).

RESULTS

During the study period, 1000 patients were recruited for the study, and among those patients, 109 were found to be admitted through EMD with drug-related problems.

Incidence

Incidence is the measure of probability of occurrence of a given medical condition in a population with a specified period of time. The incidence of DRPs in our study was found to be 10.9%.

Categorization of DRPs as per hepler and strand classification

The Hepler and Strand classification classifies the DRPs into 8 categories. In our study, the 109 DRPs had 5 categories. The DRP most experienced by the patients was found to be ADR 76 (69.7%) followed by non-
adherence 30 (27.5%). Untreated indication, sub-therapeutic dose, and
overdosage were found one case each (0.91%) (Table 1 and Fig. 1).

**ADRs and its incidence**

Of the 109 DRPs found, 76 of them were found to be ADRs. It constituted
the major part of the DRPs from EMD.

The likelihood of the DRP due to ADR was assessed using Naranjo scale.
In that, 6.42% were definite, 39.44% were probable, 22.01% were
possible, and 1.83% was found to be doubtful (Fig. 2).

**Gender-wise distribution of ADR and non-adherence**

A total of 76 males (69%) and 33 females (31%) were found to have
DRPs during the study.

It was found that male patients had more ADRs (63.1%) than females
(36.8%), and cases of non-adherence were also more in the cases of
males (60%) than in females (40%) (Fig. 3).

The association of the gender with the occurrence of DRPs was
calculated with the odds ratio formula. It was found that there was
significant association between the occurrence of DRP and gender
(*p<0.005).

**System most affected by DRPs**

Of the 109 DRPs found in the study, it was found that the organ system
most involved in DRP was neurology system (26.60%), gastrointestinal
system (23.85%), immunology system (13.76%), nephrology system
(10.1%), hematology system (8.25%), endocrinology system (7.33%),
and cardiovascular system (5.50%).

**Age-wise distribution of DRPS**

About 1000 participants were enrolled in this study. In that, the age
groups were classified into 3 major categories. Group 1 included
participants from age 0 to 18, Group 2 included participants of age
between 19 and 60, and Group 3 consisted of participants with age
above 60. In our study, it was found that the most number of DRPs
occurred in Group 2 (19–60) followed by Group 3 (>60) (Fig. 4).

The association of the occurrence of DRP with age groups was calculated
and it was found to be not significant (*p > 0.05).

**DRPs and comorbid conditions**

The occurrence of DRP is closely associated with the presence of comorbid
conditions. It was found that a significant higher risk of DRPs in patients
with comorbidities. The major comorbid conditions found in patients
with DRPs were T2DM (28.5%), HTN (31.4%), and DLP (20%) (Table 2).

Association of comorbidities with DRPs was calculated using odds ratio,
and it was found to have a significant association with the occurrence
of DRPs (*p<0.05)

**DRPs and polypharmacy**

In our study, of the 1000 patients studied, 588 patients were taking
more than one medication (polypharmacy), and from the 109 patients
with DRPs, 30 patients were found to have polypharmacy.

The association of polypharmacy with the occurrence of the DRPs was
checked using odds ratio.

The p value for this was found to be significant (*p<0.05), so
polypharmacy was found to be a significant risk factor for DRPs.

**DRPs and alcohol**

Alcohol was taken as a risk factor for the development for DRP. In our
study, on 1000 patients, it was found that 102 patients had alcohol as
a risk factor, and in that, 7 patients were found to have developed DRP.

The association of the DRP was calculated and was found to be
significant with the help of odds ratio and it was found that there was
no significant association for alcohol with that of DRPs (*p>0.05).

**Drugs associated with the DRPs**

The most common drug groups associated with DRPs were
antithrombotic agents (27%); antihypertensive (15%); antibiotics

| S. No. | Conditions | Comorbidities in patients with DRP | Percentage | Comorbidities in patients with NDRPs | Percentage |
|--------|------------|-----------------------------------|------------|-------------------------------------|------------|
| 1      | T2DM       | 20                                | 28.5       | 95                                  | 9.69       |
| 2      | HTN        | 36                                | 51.4       | 107                                 | 11.09      |
| 3      | DLP        | 14                                | 20         | 20                                  | 2.02       |

**Table 1: Organ systems most affected due to DRPs**

| S. No. | System       | Number | Percentage |
|--------|--------------|--------|------------|
| 1      | Hematology   | 9      | 8.25       |
| 2      | Nephrology   | 11     | 10.1       |
| 3      | Gastrointestinal | 26   | 23.85      |
| 4      | Endocrinology| 8      | 7.33       |
| 5      | Neurology    | 29     | 26.60      |
| 6      | Rheumatology | 1      | 0.91       |
| 7      | Immunology   | 15     | 13.76      |
| 8      | Psychiatry   | 2      | 1.83       |
| 9      | Cardiovascular| 6    | 5.50       |
| 10     | Others       | 2      | 1.83       |

**Table 2: List of comorbidities found in the patients**

| S. No. | Conditions | Comorbidities in patients with DRP | Percentage | Comorbidities in patients with NDRPs | Percentage |
|--------|------------|-----------------------------------|------------|-------------------------------------|------------|
| 1      | T2DM       | 20                                | 28.5       | 95                                  | 9.69       |
| 2      | HTN        | 36                                | 51.4       | 107                                 | 11.09      |
| 3      | DLP        | 14                                | 20         | 20                                  | 2.02       |
(12%); anti-TB agents (9%); steroids (8%); immunosuppressant's (5%); antidiabetic, antiretroviral agents, and antipsychotic agents (4%); antithyroid agents and NSAIDs (3%) followed by oral contraceptives (1%); antigout agents (1%); PPIs (1%); opioids (1%); anticonvulsants (1%); and antidepressants (1%) (Fig. 5).

Outcomes associated with DRPs

The outcome most associated with DRP was found to be CVA and seizures (11.92%), rashes (11%), bleeding (9.17%), and gastritis (7.33%). Most of the outcomes were due to the ADRs and non-adherence to the medications and most of them were preventable (Table 3).

**DISCUSSION**

Drug-related visits to the ED constitute a significant problem that contributes to the overall pressure on our health-care system. In our study, the incidence of DRP in 1000 patients admitted through EMD was checked and it was about 10.9% of the population. Many DRP-based retrospective studies identified them in the range of 0.86–10.6% [5]. Strand et al. classified DRP into eight categories focusing more on DRPs themselves than on why they occur. The most commonly presented DRPs were adverse drug reactions or side-effects of drugs as well as non-adherence to drugs such as antibiotics [6]. In our study, it was found that ADRs and non-adherence to antiepileptics caused the most number of DRPs. Adverse drug reactions can have major impacts with several meta-analyses reporting around 5% of admissions due to ADRs [6]. In our study, ADR was the most occurring DRP found with almost 76 cases to support. The system most affected by ADRs was found to be GI system (47.5%) followed by immune system [7,8]. Our study showed that neurological system was the most affected due to DRPs followed by gastrointestinal system.

Specific risk factors facilitate the occurrence of DRP. Various studies have determined numerous risk factors for DRPs. Females, polypharmacy, administration of drugs with narrow therapeutic range, age > 65, use of oral anticoagulants, and diuretics, where identified as relevant risk factors for ADEs and ADRs [9]. In our study, ADR was the most occurring DRP found with almost 76 cases to support. The system most affected by ADRs was found to be GI system (47.5%) followed by immune system [7,8]. Our study showed that neurological system was the most affected due to DRPs followed by gastrointestinal system.

Table 3: Diagnosis associated with DRPs

| S. No. | Diagnosis          | Number | Percentage | DRP   |
|-------|--------------------|--------|------------|-------|
| 1.    | Diarrhea           | 1      | 0.91       | ADR   |
| 2.    | CVA                | 13     | 11.92      | ADR, NA, untreated indication |
| 3.    | Hypokalemia        | 3      | 2.75       | ADR   |
| 4.    | Ataxia             | 1      | 0.91       | ADR   |
| 5.    | neurotoxicity      | 1      | 0.91       | ADR   |
| 6.    | Cholestasis        | 1      | 0.91       | ADR   |
| 7.    | Schizophrenia      | 1      | 0.91       | NA    |
| 8.    | Fall               | 2      | 1.83       | ADR   |
| 9.    | Liver Injury       | 4      | 3.66       | ADR   |
| 10.   | Depression         | 2      | 1.83       | NA    |
| 11.   | Hemolytic Anemia   | 4      | 3.66       | ADR   |
| 12.   | RV Infection       | 1      | 0.91       | NA    |
| 13.   | Flu-like syndrome  | 1      | 0.91       | ADR   |
| 14.   | Hyperkalemia       | 3      | 2.75       | ADR   |
| 15.   | Headache           | 1      | 0.91       | ADR   |
| 16.   | Leukopenia         | 1      | 0.91       | ADR   |
| 17.   | Thrombocytopenia   | 2      | 1.83       | ADR   |

Fig. 2: Likelihood of ADR

Fig. 3: Occurrence of ADR and non-adherence in males and females

Fig. 4: Distribution of DRPs in various age groups

(12%); anti-TB agents (9%); steroids (8%); immunosuppressant's (5%); antidiabetic, antiretroviral agents, and antipsychotic agents (4%); antithyroid agents and NSAIDs (3%) followed by oral contraceptives (1%); antigout agents (1%); PPIs (1%); opioids (1%); anticonvulsants (1%); and antidepressants (1%) (Fig. 5).
dynamics level, alcohol enhances the deleterious effects of sedatives, certain anxiolytics, antipsychotics, and anticholinergic agents [10]. On evaluation, 7 of 109 DRP cases had alcohol as risk factor. Our study does not support the fact that there is significant association between alcohol use and occurrence of DRP. The most common diagnosis associated with DRPs was seizures (11.9%), stroke (11.9%), rashes (11%), bleeding (9.17%), gastritis (7.33%), hyperglycemia (3.66%), edema (3.66%), and liver injury (3.6%). There is no significant difference between male and female group with respect to identify DRPs.

CONCLUSION
Drug-related problems have become a common problem for hospitalization these days. DRP poses a challenge to the clinician and that may affect the patient’s clinical outcome. Most of the DRPs were found in the adult population (19-60) admitted through EMD.

Majority of the DRP was contributed by ADR (69.7%) followed by non-compliance (27.5%) to the drug therapy. The major causative drug class found to cause DRP was antihypertensive and anticoagulants, followed by antibiotics, steroids etc. The organ system which was most affected was found to be gastrointestinal system. The major risk factors associated with DRP were found to be presence of comorbid conditions such as T2DM, HTN, DLP, and other factors such as alcohol consumption, polypharmacy etc.

The role of clinical pharmacist is much appreciated in managing DRPs. Designing one-to-one education strategies to improve medication adherence and management of ADRs can be helpful in getting a positive drug therapy outcome. A clinical pharmacist through his/her clinical accuracy can identify the DRPs early and come up with suitable solutions to resolve them. Thereby, reducing the burden of illness on the patients and the health-care costs and also resulting in a successful drug therapy.

ACKNOWLEDGEMENT
We are thankful to PSG Institute of Medical Science and Research for giving us the opportunity to perform the study. We also thank Dr. Rajesh Shankar Iyer MD, DM, Department of Neurology and medical staffs of PSG Hospitals, Coimbatore, Tamil Nadu, for their constant support throughout the study.

LIMITATIONS
A significant number of patients with minor DRPs have been missed from the outpatient department and the major departments since we focused on the patients admitted through emergency department only.

AUTHORS CONTRIBUTION
Alaka Prakash conceptualized the research idea, performed literature search, and wrote the manuscript. Akshay TL edited the manuscript, Ashiq Mohamed Anas and S.Diwahar revised the manuscript, and P.Rama guided throughout the research and acted as the corresponding author.

CONFLICTS OF INTEREST
The authors declare that there are no conflicts of interest.

FUNDING
This research did not receive any specific grant from funding agencies in the public, commercial, or non-for-profit sectors.

REFERENCES
1. Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med 1995;155:1949-56.
2. Royal S, Smeetan L, Avery AJ, Hurwitz B, Sheikh A. Interventions in primary care to reduce medication related adverse events and hospital admissions: Systematic review and meta-analysis. Qual Saf Health Care 2006;15:23-31.
3. Busto U, Naranjo CA, Sellers EM. Comparison of two recently published algorithms for assessing the probability of adverse drug reactions. Br J Clin Pharmacol 1982;13:223-7.
4. Al-Arifi M, Abu-Hashem H, Al-Meziny M, Said R, Aljadhey H. Emergency department visits and admissions due to drug related problems at Riyadh Military Hospital (RMH), Saudi Arabia. Saudi Pharm J 2014;22:17-25.
5. Nair NP, Chalmers L, Peterson GM, Berezwicki BJ, Castelino RL, Berezwicki LR. Hospitalization in older patients due to adverse drug reactions -the need for a prediction tool. Clin Interv Aging 2016;11:497-505.
6. Easton-Carter KL, Chapman CB, Brien JE. Emergency department attendances associated with drug-related problems in paediatrics. J Paediatr Child Health 2003;39:124-9.
7. Kourorian Z, Fatatih F, Pourpak Z, Rasoolinejad M, Gholami K. Adverse drug reactions in an Iranian department of adult infectious diseases. East Mediterr Health J 2009;15:1351-7.
8. Krähenbühl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewé J, Krähenbühl S. Drug-related problems in hospitals: A review of the recent literature. Drug Saf 2007;30:379-407.
9. Hohl CM, Dankoff J, Colacone A, Alfaiola M. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med 2001;38:666-71.
10. Laisi U, Linnoila M, Seppälä T, Himberg JI, Mattila MJ. Pharmacokinetic and pharmacodynamic interactions of diazepam with different alcoholic beverages. Eur J Clin Pharmacol 1979;16:263-70.